Search
Research
Prospects for the future: supporting the elimination of rheumatic heart disease – a National Heart, Lung, and Blood Institute Workshop ProceedingsJonathan Carapetis AM JR AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Research
Tertiary prevention and treatment of rheumatic heart disease: a National Heart, Lung, and Blood Institute working group summaryAlthough entirely preventable, rheumatic heart disease, a disease of poverty and social disadvantage resulting in high morbidity and mortality, remains an ever-present burden in low-income and middle-income countries and rural, remote, marginalised and disenfranchised populations within high-income countries.
Research
Surgery for rheumatic heart disease in the Northern Territory, Australia, 1997-2016: what have we gained?Between 1964 and 1996, the 10-year survival of patients having valve replacement surgery for rheumatic heart disease (RHD) in the Northern Territory, Australia, was 68%. As medical care has evolved since then, this study aimed to determine whether there has been a corresponding improvement in survival.
Research
Rheumatic heart disease in The Gambia: clinical and valvular aspects at presentation and evolution under penicillin prophylaxisRheumatic heart disease (RHD) remains the leading cause of cardiac-related deaths and disability in children and young adults worldwide. In The Gambia, the RHD burden is thought to be high although no data are available and no control programme is yet implemented. We conducted a pilot study to generate baseline data on the clinical and valvular characteristics of RHD patients at first presentation, adherence to penicillin prophylaxis and the evolution of lesions over time.
Research
Rheumatic heart disease in Indigenous young peoplesIndigenous children and young peoples live with an inequitable burden of acute rheumatic fever and rheumatic heart disease. In this Review, we focus on the epidemiological burden and lived experience of these conditions for Indigenous young peoples in Australia, New Zealand, and Canada. We outline the direct and indirect drivers of rheumatic heart disease risk and their mitigation.
Research
Quality of benzathine penicillin G: A multinational cross-sectional studyBenzathine penicillin G (BPG) is used as first-line treatment for most forms of syphilis and as secondary prophylaxis against rheumatic heart disease (RHD). Perceptions that poor quality of BPG is linked to reported adverse effects and therapeutic failure may impact syphilis and RHD control programs. Clinical networks and web-based advertising were used to obtain vials of BPG from a wide range of countries.
Research
Acute Rheumatic Fever and Rheumatic Heart DiseaseAcute Rheumatic Fever and Rheumatic Heart Disease is a concise, yet comprehensive, clinical resource highlighting must-know information on rheumatic heart disease and acute rheumatic fever from a global perspective
Research
The end rheumatic heart disease in Australia study of epidemiology (ERASE) project: Data sources, case ascertainment and cohort profileThe ERASE Project has created an unprecedented linked administrative database on acute rheumatic fever and rheumatic heart disease in Australia
Research
Qualitative Evaluation of a Complex Intervention to Improve Rheumatic Heart Disease Secondary ProphylaxisA multifaceted intervention was implemented using quality improvement and chronic care model approaches to improve delivery of penicillin prophylaxis for rheumatic heart disease
Research
Improving delivery of secondary prophylaxis for rheumatic heart disease in a high-burden setting: Outcome of a stepped-wedge, community, randomized trialThis strategy did not improve adherence to rheumatic heart disease secondary prophylaxis within the study time frame.